Press Releases

October 22, 2019

Chimeron Bio Announces Appointment of Dr. Robert (Bob) Willette to its Scientific Advisory Board

PHILADELPHIA–Chimeron Bio, an RNA therapy company based in Philadelphia pioneering a novel class of RNA therapeutics and vaccines, today announced the appointment of Dr. Robert (Bob) Willette to its Scientific Advisory Board. As a leader in metabolic disorders Dr. Willette will provide counsel on drug discovery and development strategies to propel the advancement of Chimeron Bio’s pipeline and the creation of transformative drugs for patients in need.

“We are delighted to welcome Bob, a seasoned and highly respected scientist, pharmacologist and a leader to Chimeron Bio as we focus on metabolic disorders as a key component of our pipeline” said Jolly Mazumdar, CEO of the company.  “Bob’s extensive experience in metabolic disorders aligns with the company’s direction and makes him well positioned to advance our work in liver and kidney diseases.”

“I have had many opportunities over the course of my career to work with different technologies and shape drug development programs, and I am excited to bring those experiences to Chimeron Bio” commented Bob. “I am looking forward to working with the company’s talented team to advance preclinical development programs and build a robust pipeline in liver and kidney diseases that address urgent unmet medical needs and transform patient care.”

Dr. Bob Willette is an eminent discovery pharmacologist, a pharmaceutical industry veteran and a cardiovascular and metabolic disorders expert. He is the founder and president of POC Pharma Consulting, offering strategic advice to discovery and development companies. Previously, he spent over thirty years in the pharmaceutical industry, most recently serving as the Vice President, Head and Senior Fellow of GSK’s Heart Failure & Renal Discovery Performance Unit. During his industry tenure Bob has led and advanced multiple internal discovery programs and alliances across therapeutic modalities. He is the recipient of American Heart Association’s Robert Seikert award for outstanding contribution to stroke research and the George Koelle award for contributions in Pharmacology. Bob has authored >150 original peer reviewed research papers and his other notable accomplishments include President of the Mid-Atlantic Pharmacology Society, adjunct professorship at Thomas Jefferson University, scientific advisor to the Nephcure Foundation and he currently serves as an industry mentor at the University of Pennsylvania, interim CSO at Complexa Therapeutic, Inc. and consulting CSO at Immuno Met, Inc.

Bob received his doctoral degree from the Department of Pharmacology at Rutgers University, School of Medicine and Dentistry in New Jersey and pursued his postdoctoral training in cardiopulmonary biology at the Veterans Administration in NJ and Department of Neurosurgery.

About Chimeron Bio

Chimeron Bio is a biotechnology company focused on the research of self-amplifying RNA (saRNA) towards development of novel RNA entities for various diseases. The company is using its proprietary ChaESAR platform to develop a pipeline in oncology, rare genetic disorders and infectious diseases.  For more information, visit

Media Inquiries

Interested in learning more about Chimeron Bio’s novel technology and the work we are doing to develop first-in-class self-amplifying RNA therapeutics?

Reach out to us at today.

Follow Us